Denali Therapeutics Stock Price Prediction

DNLI Stock  USD 24.69  0.47  1.94%   
The RSI of Denali Therapeutics' share price is above 70 as of 25th of November 2024 suggesting that the stock is becoming overbought or overvalued. The idea behind Relative Strength Index (RSI) is that it helps to track how fast people are buying or selling Denali, making its price go up or down.

Oversold Vs Overbought

70

 
Oversold
 
Overbought
The successful prediction of Denali Therapeutics' future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Denali Therapeutics, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Denali Therapeutics' stock price prediction:
EPS Estimate Next Quarter
(0.62)
EPS Estimate Current Year
(2.76)
EPS Estimate Next Year
(2.86)
Wall Street Target Price
41.6923
EPS Estimate Current Quarter
(0.61)
Using Denali Therapeutics hype-based prediction, you can estimate the value of Denali Therapeutics from the perspective of Denali Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Denali Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Denali because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Denali Therapeutics after-hype prediction price

    
  USD 24.77  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Denali Therapeutics Basic Forecasting Models to cross-verify your projections.
For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.
Intrinsic
Valuation
LowRealHigh
22.2231.7035.12
Details
Naive
Forecast
LowNextHigh
16.8320.2523.68
Details
17 Analysts
Consensus
LowTargetHigh
50.6055.6061.72
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.73-0.69-0.65
Details

Denali Therapeutics After-Hype Price Prediction Density Analysis

As far as predicting the price of Denali Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Denali Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Denali Therapeutics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Denali Therapeutics Estimiated After-Hype Price Volatility

In the context of predicting Denali Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Denali Therapeutics' historical news coverage. Denali Therapeutics' after-hype downside and upside margins for the prediction period are 21.35 and 28.19, respectively. We have considered Denali Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
24.69
24.77
After-hype Price
28.19
Upside
Denali Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of Denali Therapeutics is based on 3 months time horizon.

Denali Therapeutics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Denali Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Denali Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Denali Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.04 
3.42
  0.08 
  0.03 
9 Events / Month
16 Events / Month
In about 9 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
24.69
24.77
0.32 
163.64  
Notes

Denali Therapeutics Hype Timeline

Denali Therapeutics is currently traded for 24.69. The entity has historical hype elasticity of 0.08, and average elasticity to hype of competition of -0.03. Denali is expected to increase in value after the next headline, with the price projected to jump to 24.77 or above. The average volatility of media hype impact on the company the price is about 163.64%. The price growth on the next news is projected to be 0.32%, whereas the daily expected return is currently at 0.04%. The volatility of related hype on Denali Therapeutics is about 412.73%, with the expected price after the next announcement by competition of 24.66. The company reported the previous year's revenue of 330.53 M. Net Loss for the year was (145.22 M) with loss before overhead, payroll, taxes, and interest of (250.27 M). Given the investment horizon of 90 days the next expected press release will be in about 9 days.
Check out Denali Therapeutics Basic Forecasting Models to cross-verify your projections.
For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.

Denali Therapeutics Related Hype Analysis

Having access to credible news sources related to Denali Therapeutics' direct competition is more important than ever and may enhance your ability to predict Denali Therapeutics' future price movements. Getting to know how Denali Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Denali Therapeutics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
FIXXHomology Medicines(0.01)2 per month 3.52  0.01  5.77 (5.61) 19.43 
STOKStoke Therapeutics(0.04)10 per month 0.00 (0.09) 4.68 (6.99) 21.35 
BCELAtreca Inc 0.00 0 per month 5.00  0.01  7.53 (9.65) 23.80 
BDTXBlack Diamond Therapeutics 0.18 7 per month 0.00 (0.30) 5.56 (8.30) 19.51 
FDMT4D Molecular Therapeutics 0.21 9 per month 0.00 (0.24) 5.15 (5.78) 25.71 
ASNDAscendis Pharma AS(2.73)9 per month 0.00 (0.06) 4.75 (3.56) 22.16 
APLSApellis Pharmaceuticals(1.10)9 per month 0.00 (0.13) 4.31 (5.17) 15.97 
BGNEBeiGene(1.99)7 per month 0.00 (0.06) 3.46 (4.40) 13.85 
AKROAkero Therapeutics(0.28)9 per month 2.66  0.08  5.23 (4.45) 13.37 
BPMCBlueprint Medicines Corp(1.72)8 per month 2.61 (0.03) 4.90 (3.62) 14.28 
LEGNLegend Biotech Corp 0.01 10 per month 0.00 (0.19) 4.29 (5.82) 17.18 
PCVXVaxcyte(10.51)10 per month 2.19  0.03  3.16 (4.09) 42.81 
TVTXTravere Therapeutics(0.30)11 per month 1.92  0.25  11.58 (4.13) 23.97 
CERECerevel Therapeutics Holdings 0.20 9 per month 0.94 (0.04) 1.91 (1.59) 6.40 
RNAAvidity Biosciences 0.13 12 per month 4.19 (0.01) 5.78 (7.08) 27.94 
RVMDRevolution Medicines 1.13 10 per month 2.04  0.12  4.81 (3.24) 10.95 
DAWNDay One Biopharmaceuticals 0.23 9 per month 2.72 (0.04) 3.84 (3.69) 11.44 
SWTXSpringWorks Therapeutics(1.08)11 per month 0.00 (0.05) 4.86 (4.36) 12.80 
GLUEMonte Rosa Therapeutics(0.25)9 per month 3.86  0.08  10.11 (8.18) 102.66 
DSGNDesign Therapeutics(0.24)5 per month 5.31  0.04  9.61 (8.21) 35.31 
HOWLWerewolf Therapeutics(0.02)6 per month 4.85 (0.01) 9.21 (8.75) 49.02 
IKNAIkena Oncology(0.05)4 per month 1.39 (0.07) 1.81 (1.74) 13.50 

Denali Therapeutics Additional Predictive Modules

Most predictive techniques to examine Denali price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Denali using various technical indicators. When you analyze Denali charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Denali Therapeutics Predictive Indicators

The successful prediction of Denali Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Denali Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Denali Therapeutics based on analysis of Denali Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Denali Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Denali Therapeutics's related companies.
 2022 2023 2024 (projected)
Graham Number22.0313.3612.69
Receivables Turnover11.6996.65101.48

Story Coverage note for Denali Therapeutics

The number of cover stories for Denali Therapeutics depends on current market conditions and Denali Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Denali Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Denali Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Denali Therapeutics Short Properties

Denali Therapeutics' future price predictability will typically decrease when Denali Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Denali Therapeutics often depends not only on the future outlook of the potential Denali Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Denali Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding137.4 M
Cash And Short Term InvestmentsB

Complementary Tools for Denali Stock analysis

When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities